Document is current
Any future updates will be listed below
-
Authors
Raines, Lydia N.
Zhao, Haoxin
Wang, Yuzhu
Chen, Heng-Yi https://orcid.org/0000-0001-9283-6144
Gallart-Ayala, Hector
Hsueh, Pei-Chun
Cao, Wei
Koh, Yeojung https://orcid.org/0000-0002-4294-7871
Alamonte-Loya, Ana
Liu, Pu-Ste
Ivanisevic, Julijana https://orcid.org/0000-0001-8267-2705
Lio, Chan-Wang Jerry
Ho, Ping-Chih https://orcid.org/0000-0003-3078-3774
Huang, Stanley Ching-Cheng https://orcid.org/0000-0002-6557-3737
-
Funding
Funding for this research was provided by:
Case Comprehensive Cancer Center, Case Western Reserve University (IRG-91-022-19, IRG-16-186-21, 5P50CA150964-08)
Case Western Reserve University (1P30DK097948)
School of Medicine, Case Western Reserve University (AI089474)
Ohio State University
Cancer Research Institute
- License Information
-
More Information
Article History
Received: 20 January 2021
Accepted: 18 January 2022
First Online: 28 February 2022
Competing interests
: P.-C.H. is a member of the scientific advisory for Elixiron Immunotherapeutics. The remaining authors declare no competing interests.
